When Fewer Complications Cost More: A Value-Based Reanalysis of Donor-Site Reconstruction.

Abstract

Reconstructive strategies are commonly evaluated according to complication rates and technical success at the individual patient level. However, interventions that reduce complications may simultaneously increase cumulative procedural exposure, operative utilization, and healthcare resource consumption across patient populations. This distinction reflects a broader epidemiologic trade-off between universal prophylactic intervention and selective escalation following clinically significant failure. We performed a value-based reinterpretation of the donor-site reconstruction study by Angela Alnemri et al., comparing staged reconstruction of radial forearm free flap donor sites using Integra followed by delayed split-thickness skin grafting (STSG) with primary STSG closure. Using published cohort data, we conducted a composite procedural burden analysis evaluating cumulative donor-site closure procedures under observed treatment patterns and under a procedural-economy counterfactual in which all patients underwent primary STSG with selective operative salvage only when clinically necessary. The original study demonstrated lower rates of skin graft breakdown and tendon exposure with staged reconstruction. However, staged reconstruction required a second operative episode for nearly all patients by design, resulting in substantially greater cumulative procedural exposure. Across 179 patients, the observed treatment strategy resulted in 313 donor-site closure procedures. In contrast, the modeled procedural-economy strategy resulted in 179 + r procedures, where r represented patients requiring operative salvage following donor-site complications. Under the base-case assumption (r = 0), this corresponded to 134 fewer operative procedures. Even under conservative sensitivity assumptions permitting selective reoperation, substantial procedural reduction persisted before parity with universal staging was reached. Lower complication rates do not necessarily translate into lower healthcare utilization or greater value at the population level. In donor-site reconstruction, staged strategies reduce individual-level morbidity but do so through universal escalation of procedural intensity. Reconstructive decision-making should therefore incorporate procedural economy, operative exposure, and health-system resource utilization alongside conventional complication-based endpoints. Integrating epidemiologic and health-economic principles into reconstructive algorithms may better align technical outcomes with value-based surgical care.